Login to Your Account

Praecis' Early Phase II/III Data Strong For Endometriosis Drug

By Randall Osborne

Thursday, June 20, 2002
Praecis Pharmaceuticals Inc., in the process of overcoming an FDA snag in its bid for Plenaxis as a prostate cancer treatment, revealed positive early data with the gonadotropin-releasing hormone agonist in a Phase II/III endometriosis study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription